Institute for Biology and Biotechnology of Plants, University of Münster, 48143 Münster, Germany.
Int J Mol Sci. 2020 Oct 22;21(21):7835. doi: 10.3390/ijms21217835.
During the past decade, detailed studies using well-defined 'second generation' chitosans have amply proved that both their material properties and their biological activities are dependent on their molecular structure, in particular on their degree of polymerisation (DP) and their fraction of acetylation (). Recent evidence suggests that the pattern of acetylation (PA), i.e., the sequence of acetylated and non-acetylated residues along the linear polymer, is equally important, but chitosan polymers with defined, non-random PA are not yet available. One way in which the PA will influence the bioactivities of chitosan polymers is their enzymatic degradation by sequence-dependent chitosan hydrolases present in the target tissues. The PA of the polymer substrates in conjunction with the subsite preferences of the hydrolases determine the type of oligomeric products and the kinetics of their production and further degradation. Thus, the bioactivities of chitosan polymers will at least in part be carried by the chitosan oligomers produced from them, possibly through their interaction with pattern recognition receptors in target cells. In contrast to polymers, partially acetylated chitosan oligosaccharides (paCOS) can be fully characterised concerning their DP, , and PA, and chitin deacetylases (CDAs) with different and known regio-selectivities are currently emerging as efficient tools to produce fully defined paCOS in quantities sufficient to probe their bioactivities. In this review, we describe the current state of the art on how CDAs can be used in forward and reverse mode to produce all of the possible paCOS dimers, trimers, and tetramers, most of the pentamers and many of the hexamers. In addition, we describe the biotechnological production of the required fully acetylated and fully deacetylated oligomer substrates, as well as the purification and characterisation of the paCOS products.
在过去的十年中,使用定义明确的“第二代”壳聚糖进行的详细研究充分证明,它们的材料性质和生物活性都取决于其分子结构,特别是其聚合度 (DP) 和乙酰化度 (). 最近的证据表明,乙酰化模式 (PA),即线性聚合物上乙酰化和非乙酰化残基的序列,同样重要,但具有定义的、非随机 PA 的壳聚糖聚合物尚不可用。PA 会影响壳聚糖聚合物生物活性的一种方式是它们被目标组织中存在的序列依赖性壳聚糖水解酶酶解。聚合物底物的 PA 与水解酶的亚位偏好相结合,决定了寡聚物产物的类型及其产生和进一步降解的动力学。因此,壳聚糖聚合物的生物活性至少部分将由它们产生的壳聚糖寡聚物携带,可能通过它们与靶细胞中模式识别受体的相互作用。与聚合物不同,部分乙酰化壳聚糖寡糖 (paCOS) 可以在 DP、和 PA 方面得到充分表征,并且具有不同且已知区域选择性的几丁质脱乙酰酶 (CDAs) 当前作为有效工具出现,可用于以足够的数量生产完全定义的 paCOS,以探测其生物活性。在这篇综述中,我们描述了当前的最新技术状态,即 CDAs 如何在前向和反向模式下用于生产所有可能的 paCOS 二聚体、三聚体和四聚体、大多数五聚体和许多六聚体。此外,我们还描述了所需完全乙酰化和完全脱乙酰化寡聚物底物的生物技术生产,以及 paCOS 产物的纯化和表征。